Clinical study of adjuvant capecitabine monotherapy in chinese elderly patients (Aged 55-70) with stage IIa breast cancer

Onkologie

Volumn 33, Issue 8-9, 2010, Pages 433-436

  Hu, Wei ^a   Shi, Junyi ^a   Sheng, Yuan ^a   Li, Li ^a   Su, Dongwei ^a   Wang, Chi Kun ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Capecitabine; Chemotherapy; Elderly patients; Overall survival; Quality of life

Indexed keywords

AROMATASE INHIBITOR; CAPECITABINE; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; PYRIDOXINE; TAMOXIFEN;

ADJUVANT THERAPY; ADULT; AGED; AGING; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANXIETY DISORDER; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE MARROW SUPPRESSION; BREAST CANCER; BREAST METASTASIS; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CHINESE; CONTROLLED STUDY; DENTAL ULCER; DEPRESSION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HEART MUSCLE ISCHEMIA; HUMAN; LIVER INJURY; LIVER TOXICITY; MAJOR CLINICAL STUDY; MASTECTOMY; MENTAL DISEASE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHLEBITIS; QUALITY OF LIFE; SIDE EFFECT; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHINA; CYCLOPHOSPHAMIDE; CYTARABINE; DEOXYCYTIDINE; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; NEOPLASM STAGING; TREATMENT OUTCOME;

EID: 77956624687     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000317267     Document Type: Article

References (21)

1. Key TJ, Verkasalo PK, Banks E: Epidemiology of breast cancer. Lancet Oncol 2001;2:133-140.
2. Du XL, Jones DN, Zhang D: Effectiveness of adjuvant chemotherapy for node-positive operable breast cancer in older women. J Gerontol A Biol Sci Med Sci 2005;60:1137-1144.
3. Jemal A, Siegel R, Ward E, et al.: Cancer statistics, 2009. CA Cancer J Clin 2009 CA;59:225-249.
4. Yancik R, Wesley MN, Ries LA, et al.: Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 2001;285:885-892.
5. Wildiers H, Kunkler I, Biganzoli L, et al.: Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology. Lancet Oncol 2007;8:1101-1115. (Pubitemid 350182967)
6. Reed SD, Li Y, Anstrom KJ, et al.: Cost effectiveness of ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2009;27:2185-2191.
7. Finek J, Holubec L Jr, Svoboda T, et al.: A phase II trial of oral vinorelbine and capecitabine in anthracycline pretreated patients with metastatic breast cancer. Anticancer Res 2009;29:667-670.
8. Chan S, Romieu G, Huober J, et al.: Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. J Clin Oncol 2009;27:1753-1760.
9. Blum JL, Jones SE, Buzdar AU, et al.: Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999;17: 485-493.
10. Gradishar WJ: Clinical status of capecitabine in the treatment of breast cancer. Oncology (Williston Park) 2001;15:69-71.
11. Waters SH, Gillibrand A, Berry H, et al.: Dosefinding study of weekly docetaxel, epirubicin and capecitabine, as first-line treatment in advanced breast cancer. Cancer Chemother Pharmacol 2009; 64:407-412.
12. Michalaki V, Gennatas S, Gennatas K: Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results. Anticancer Drugs 2009;20:204-207.
13. Aprile G, Mazzer M, Moroso S, et al.: Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer. Anticancer Drugs 2009;20:217-229.
14. Miwa M, Ura M, Nishida M, et al.: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998;34:1274-1281.
15. Greene FL, Page DL, Fleming ID, et al.(eds): AJCC Cancer Staging Manual, 6th ed. New York, NY, Springer, 2002.
16. Yang L, Wang JW, Cui CX, et al.: Tolerability of oxaliplatin-based adjuvant chemotherapy in colorectal cancer patients. Cancer Res Prev Treat 2008;35:892-896.
17. Shen ZZ, Liu GY, Su FX, et al.: Neoadjuvant chemotherapy with docetaxel plus epirubicin for locally advanced breast cancer: a multicenter phase II study. Chin J Oncol;2005;27:126-128.
18. Trotti A, Colevas AD, Setser A, et al.: CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13:176-181.
19. Schag CC, Heinrich RL, Ganz PA: Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncology 1984;2:187-193.
20. Grant S, Aitchison T, Henderson E, et al.: A comparison of the reproducibility and the sensitivity to change of visual analogue scales, Borg scales, and Likert scales in normal subjects during submaximal exercise. Chest 1999;116:1208-1217.
21. Muss HB, Berry DA, Cirrincione CT, et al.: Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med 2009;360: 2055-2065.